Grifols Announces Transfer of Management of Melville, New York Plasma Fractionation Facility to Kedrion
Today Grifols, S.A. (Grifols) announced that effective July 1, 2013, it will transfer management of the Melville, New York plasma fractionation facility to Kedrion. This action is being taken in accordance with previously disclosed terms of the 2011 U.S. Federal Trade Commission (FTC) consent order permitting Grifols acquisition of Talecris Biotherapeutics, Inc.
Among other things, the FTC order required Grifols to manage the Melville facility for a period of up to four years and the purification of certain intermediate plasma products produced at the facility for a seven year period. Although Grifols is now transferring management of the fractionation facility to Kedrion, Grifols will continue to purify certain intermediate plasma products from the New York facility on behalf of Kedrion and in accordance with the terms of the FTC order.
Grifols and Kedrion will work together to ensure a smooth and successful management transfer process. Employees at the Melville facility will be a part of the transfer of management to Kedrion. Grifols is deeply appreciative of the effort and commitment of the employees at the Melville facility and joins them in celebrating this important milestone.
Grifols is a global healthcare company with a 70-year legacy of improving people's health and well being through the development of life-saving plasma medicines, hospital pharmacy products and diagnostic technology for clinical use. As a leading producer of plasma medicines, Grifols has a presence in more than 100 countries and is the world leader in plasma collection, with 150 plasma donation centers across the U.S. Grifols is committed to increasing patient access to its life-saving plasma medicines through significant manufacturing expansions and the development of new therapeutic applications of plasma proteins. The company is headquartered in Barcelona, Spain and employs more than 11,000 people worldwide.
In 2012, Grifols' sales exceeded 2,620 million euros. The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ: GRFS). For more information visit www.grifols.com